Compositions and methods for combination antiviral therapy

Details for Australian Patent Application No. 2004206821 (hide)

Owner Gilead Sciences, Inc.

Inventors Oliyai, Reza; Dahl, Terrence C.; Menning, Mark M.

Agent Phillips Ormonde Fitzpatrick

Pub. Number AU-B-2004206821

PCT Pub. Number WO2004/064845

Priority 60/440 246 14.01.03 US; 60/440,308 14.01.03 US

Filing date 13 January 2004

Wipo publication date 5 August 2004

Acceptance publication date 26 February 2009

International Classifications

A61K 31/675 (2006.01) - having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate

A61K 31/513 (2006.01) - having oxo groups directly attached to the heterocyclic ring, e.g. cytosine

A61K 31/7076 (2006.01)

A61K 45/06 (2006.01) Medicinal preparations containing active ingredients not provided for in groups

Event Publications

21 July 2005 PCT application entered the National Phase

  PCT publication WO2004/064845 Priority application(s): WO2004/064845

26 February 2009 Application Accepted

  Published as AU-B-2004206821

11 June 2009 Application for Amendment

  The nature of the amendment is as shown in the statement(s) filed 20 May 2009. Address for service in Australia - Phillips Ormonde Fitzpatrick Level 22 367 Collins Street Melbourne VIC 3000

1 October 2009 Amendment Made

  The nature of the amendment is as shown in the statement(s) filed 20 May 2009

8 October 2009 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004206826-Methods for making oxidation resistant polymeric material

2004206820-Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides